Literature DB >> 74243

Splenectomy in myeloid metaplasia.

E B Cabot, M F Brennan, D S Rosenthal, R E Wilson.   

Abstract

A retrospective review of 19 patients with documented myeloid metaplasia undergoing, elective splenectomy during the past ten years at the Peter Bent Brigham Hospital is presented. The primary indications for splenectomy in 17 of these 19 were either hypersplenism or symptomatic splenomegaly. Eighteen of the 19 underwent both 59Fe-ferrokinetic studies and 51Cr-sequestration studies or, alternatively, 111In-marrow scintigraphy as a part of their routine preoperative evaluation. The death from sepsis of one patient six weeks post-operatively, whose marrow function was poor and whose level of splenic sequestration was minimal, confirms the efficacy of these studies in the preoperative prediction of hematologic response to splenectomy. Eighteen of the 19 patients benefited from the operation in terms of symptomatic relief and/or hematologic improvement, although surgery presumably did nothing to prolong survival in these patients. We conclude that splenectomy is indicated as a palliative maneuver for carefully selected patients with myeloid metaplasia without prohibitive operative risk, provided the criteria for selection of patients are adhered to and the surgeon and hematologist work together as a team.

Entities:  

Mesh:

Year:  1978        PMID: 74243      PMCID: PMC1396399          DOI: 10.1097/00000658-197801000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  SPLENECTOMY IN MYELOFIBROSIS.

Authors:  M K JENSEN
Journal:  Acta Med Scand       Date:  1964-05

2.  SPLENECTOMY FOR AGNOGENIC MYELOID METAPLASIA AND MYELOFIBROSIS.

Authors:  N FISHMAN; W F BALLINGER
Journal:  Arch Surg       Date:  1965-02

3.  Myelofibrosis. Clinical, hematologic and pathologic study of 110 patients.

Authors:  B A BOURONCLE; C A DOAN
Journal:  Am J Med Sci       Date:  1962-06       Impact factor: 2.378

4.  Use of indium chloride scintigraphy in patients with myelofibrosis.

Authors:  B J McNeil; B L Holman; L N Button; D S Rosenthal
Journal:  J Nucl Med       Date:  1974-08       Impact factor: 10.057

5.  Sex, splenectomy, and myeloid metaplasia.

Authors:  M N Silverstein; W H ReMine
Journal:  JAMA       Date:  1974-01-28       Impact factor: 56.272

6.  Splenectomy for hematologic disorders.

Authors:  S I Schwartz; R P Bernard; J T Adams; A W Bauman
Journal:  Arch Surg       Date:  1970-08

7.  Myeloid metaplasia: a study of 98 cases.

Authors:  D S Rosenthal; W C Moloney
Journal:  Postgrad Med       Date:  1969-03       Impact factor: 3.840

Review 8.  Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia.

Authors:  J Laszlo
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

9.  Splenectomy for agnogenic myeloid metaplasia.

Authors:  M R Gomes; M N Silverstein; W H Remine
Journal:  Surg Gynecol Obstet       Date:  1967-07

10.  Myeloproliferative disorders.

Authors:  S I Schwartz
Journal:  Ann Surg       Date:  1975-10       Impact factor: 12.969

View more
  1 in total

1.  Splenectomy for myeloproliferative disorders.

Authors:  R E Wilson; D S Rosenthal; W C Moloney; R T Osteen
Journal:  World J Surg       Date:  1985-06       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.